SFM
EWTX icon

Sphera Funds Management’s Edgewise Therapeutics EWTX Stock Holding History

Sphera Funds Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60,000
Closed -$590K – 67
2022
Q3 		$590K Buy
+60,000
New +$606K 0.08% 67
2021
Q2 		– Sell
-100,000
Closed -$3.25M – 147
2021
Q1 		$3.25M Buy
+100,000
New +$3.24M 0.25% 91

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sphera Funds Management's EWTX Position: Q4 2022 in Review

Sphera Funds Management sold out of Edgewise Therapeutics (EWTX) in Q4 2022, closing a stake of 60,000 shares — an estimated $590K sold.

Sphera Funds Management first reported a position in EWTX in Q1 2021 and held it in 2 quarters. The position peaked at $3.25M in Q1 2021. 90 funds tracked by Wall St. Rank hold EWTX as of Q4 2022.

  • Sphera Funds Management reported no remaining Edgewise Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Sphera Funds Management sold 60,000 Edgewise Therapeutics shares in Q4 2022, an estimated $590K.
  • Sphera Funds Management first reported a position in Edgewise Therapeutics in Q1 2021 and held it in 2 quarters.
  • Sphera Funds Management's Edgewise Therapeutics position peaked at $3.25M in Q1 2021.
  • 90 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2022.

Based on Sphera Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.